Last reviewed · How we verify

Trifolium pratense — Competitive Intelligence Brief

Trifolium pratense (Trifolium pratense) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phytoestrogen / herbal supplement. Area: Women's Health / Menopause.

marketed Phytoestrogen / herbal supplement Estrogen receptors (ERα, ERβ) Women's Health / Menopause Small molecule Live · refreshed every 30 min

Target snapshot

Trifolium pratense (Trifolium pratense) — National Center for Complementary and Integrative Health (NCCIH). Trifolium pratense (red clover) contains isoflavones that may act as phytoestrogens, binding to estrogen receptors to modulate hormonal signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trifolium pratense TARGET Trifolium pratense National Center for Complementary and Integrative Health (NCCIH) marketed Phytoestrogen / herbal supplement Estrogen receptors (ERα, ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phytoestrogen / herbal supplement class)

  1. National Center for Complementary and Integrative Health (NCCIH) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trifolium pratense — Competitive Intelligence Brief. https://druglandscape.com/ci/trifolium-pratense. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: